TY - JOUR
T1 - ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis
AU - Okochi-Takada, E.
AU - Hattori, N.
AU - Tsukamoto, T.
AU - Miyamoto, K.
AU - Ando, T.
AU - Ito, S.
AU - Yamamura, Y.
AU - Wakabayashi, M.
AU - Nobeyama, Y.
AU - Ushijima, T.
N1 - Funding Information:
We are grateful to Dr Masabumi Shibuya, Tokyo Medical and Dental University, for his expert advice. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan and by National Cancer Center Research and Development Fund. YN is a recipient of a Research Resident Fellowships from the Foundation for Promotion of Cancer Research.
PY - 2014/4/24
Y1 - 2014/4/24
N2 - Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.
AB - Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=84899620988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899620988&partnerID=8YFLogxK
U2 - 10.1038/onc.2013.174
DO - 10.1038/onc.2013.174
M3 - Article
C2 - 23686315
AN - SCOPUS:84899620988
SN - 0950-9232
VL - 33
SP - 2273
EP - 2278
JO - Oncogene
JF - Oncogene
IS - 17
ER -